3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
12
Terminated
4
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
24
Carcinoma, Renal Cell
15
Carcinoma, Non-Small-Cell Lung
15
Neoplasm Metastasis
12
Urinary Bladder Neoplasms
6
Sarcoma
6
Prostatic Neoplasms
6
Lung Neoplasms
6
Pancreatic Neoplasms
5
Neoplasms
5
Kidney Neoplasms
5
Ovarian Neoplasms
4
Glioblastoma
4
Carcinoma, Transitional Cell
4
Uveal Melanoma
3
Small Cell Lung Carcinoma
3
Myelodysplastic Syndromes
3
Mesothelioma
3
Histiocytoma, Malignant Fibrous
3
Colorectal Neoplasms
3
Chordoma
3
Carcinoma, Neuroendocrine
3
Carcinoma, Merkel Cell
3
Breast Neoplasms
3
Brain Neoplasms
3
Urogenital Neoplasms
2
Urethral Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Interventions
balstilimab
2
tremelimumab
1
spartalizumab
1
pembrolizumab
1
lenvatinib
1
Standard of Care
1
Pemetrexed
1
Nivolumab
1
Ipilimumab
1
Carboplatin
1
Axitinib
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Ipilimumab
×
Clear all
NCT07000149
2026-03-10
eVOLVE-RCC02
AstraZeneca
Phase 3
Active not recruiting
1,116 enrolled